The biotech firm reported a GAAP EPS loss of $0.16, narrower than the anticipated $0.18 deficit.
Black Diamond Therapeutics reported a second-quarter GAAP loss per share of $0.16, beating expectations by $0.02. The narrower loss reflects improved cost management and operational efficiency during the period.
Analysts had forecasted a loss of $0.18 per share for the quarter. The company’s performance contrasts with its prior quarter, where losses were wider amid higher R&D expenditures.
Shares showed limited movement in after-hours trading as investors assessed the results.